Skip to main content

Incyte Directors Approve Two-for-One Stock Split, Tell Quarterly Results


PALO ALTO, Calif.--The board of directors of genomic database company Incyte Pharmaceuticals here has approved a two-for-one stock split that will be distributed November 7 in the form of a stock dividend. Eligible for the split are shareholders of record as of October 17. The split will increase the number of outstanding shares in the company to approximately 24 million.

The move was made primarily to bring the stock's price into a range that would have greater appeal for investors, according to Roy Whitfield, Incyte's CEO. At the same time, the company reported net income of $3 million, or 25 cents per share, for the quarter ended September 30, and $6 million, or 51 cents per share, for the nine months ending on that date. For the same periods in 1996 Incyte lost $3.4 million and $7 million, or 33 and 69 cents per share, respectively.

Officials attributed the gains to a significant increase in the number of database collaboration agreements Incyte has signed this year. In the most recent quarter, the company has announced deals with SmithKline Beecham and Organon. Among Incyte's products are the widely used LifeSeq gene sequence and expression database, LifeSeq Atlas gene mapping database, PathoSeq microbial database, and LifeSeq FL database of full-length genes. The databases integrate bioinformatics software with both proprietary and publicly available genetic information. Incyte also offers the LifeTools line of bioinformatics software products.

Filed under

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.